Cancer cells frequently alter the number of copies they carry of particular DNA segments. A deletion can remove a gene that restrains cell growth, while a gain or amplification can increase the dosage of an oncogene, intensifying signals that promote proliferation or survival. These changes, collectively called copy-number variations, may span an entire chromosome or be confined to a small genomic region containing a clinically important gene. Their patterns can help identify tumor types, distinguish biologically different disease subgroups and reveal potential treatment targets. DNA methylation arrays were originally developed primarily to measure chemical tags attached to DNA, especially methyl groups that influence gene regulation. Yet the same arrays also provide indirect information about copy number because the intensity of signals from thousands of genomic probes changes when DNA is gained or lost. CnQuant is designed to extract and organize that secondary signal, turning a widely used epigenetic assay into a broader genomic profiling tool.

The platform builds on the team’s earlier EpiDiP system and incorporates the Mepylome toolkit for processing methylation and copy-number data. Its architecture separates analysis services from the visual interfaces used by clinicians. A coordinating component, CQmanager, directs files through a local application programming interface and can be incorporated into existing diagnostic workflows, including hospital systems that must keep patient data on site. CQcalc calculates copy-number alterations using array-specific, gender-balanced reference data, which are essential because normal signal levels vary between platforms and can be affected by sex-chromosome composition. The software stores reference information in compressed, checksum-verified form to reduce storage and computational demands. Once profiles have been generated, CQall_plotter can overlay data from multiple samples and array types, while the CQall and CQcase interfaces present cohort-level and individual-patient views through a web-based graphical environment.

That distinction between population patterns and single-patient inspection is central to CnQuant’s clinical design. CQall functions as an atlas of recurrent abnormalities, allowing users to examine how often a chromosomal gain or deletion appears within a reference cohort. Such frequency information can provide a plausibility check when a new diagnostic result seems unusual, and it may also help researchers investigate the genomic architecture of rare tumors. CQcase focuses on one specimen at a time, displaying selected genomic regions at high resolution and attaching gene-level annotations to the plot. A clinician can therefore move from a broad chromosome-wide pattern to a specific locus, such as ERBB2, MDM2 or PDGFRA, or to tumor-suppressor regions including CDKN2A. The interface is intended to be usable without specialist bioinformatics training. Annotated plots can be downloaded into electronic health records or shared through links during multidisciplinary tumor-board discussions, although the researchers emphasize that the links preserve visualization and annotation rather than exposing identifying patient information.

The system’s reference strategy also addresses a subtle problem in comparing data produced by different generations of methylation arrays. A reference cohort may combine samples analyzed on the older HumanMethylation450K platform with samples processed on EPIC arrays, whose probe content is not identical. If a comparison uses probes present on only one platform, apparent differences may reflect technology rather than tumor biology. CnQuant therefore restricts cross-platform cohort analyses to genomic probes shared by all included array types. That choice can reduce the number of measurements available, but it makes comparisons more conservative and helps avoid misleading conclusions, particularly in rare tumor entities where cohorts are small and heterogeneous. The researchers report that the software supports conventional methylation-array versions and supplies the corresponding copy-number-neutral reference data, enabling a unified approach rather than requiring each laboratory to assemble its own normalization framework.

Examples shown by the investigators illustrate how chromosomal signatures can mirror recognized tumor biology. In posterior fossa pilocytic astrocytomas, the platform identified recurrent gain of chromosome 7 associated with an internal tandem duplication. In diffuse midline gliomas carrying H3K27 alterations, it highlighted frequent gain involving PDGFRA. A recurrent loss of chromosome 7 together with gain of chromosome 10 appeared in RTK II glioblastomas that lacked IDH mutations, while sporadic amplification of the ERBB2 locus was visible in breast carcinomas. These patterns are not, by themselves, substitutes for a complete diagnosis. Instead, they provide genomic context that can be interpreted alongside histology, methylation-based tumor classification, sequencing and immunohistochemistry. At the individual-gene level, a copy-number plot may help explain a high or low variant allelic frequency in parallel sequencing, or clarify whether an apparent sequencing signal is consistent with a deletion, duplication or amplification in the surrounding DNA.

To test whether the visual output corresponded to established clinical results, the team examined four groups of tumors: breast-cancer metastases, H3K27-altered diffuse midline gliomas, IDH-wild-type RTK II glioblastomas and posterior fossa pilocytic astrocytomas. The 30 cases contained oncologically relevant copy-number changes and had already been assessed using accredited diagnostic methods. Depending on the tumor, the comparison data came from second-generation DNA or RNA sequencing panels, including the Oncomine Comprehensive Assay V2 and Archer FUSIONPlex Core Solid Tumor panel, or from HER2 fluorescence in situ hybridization and immunohistochemistry. Across 155 genomic loci assessed by visual comparison, 153 matched the routine results. The 98.71 percent figure is encouraging, but it comes from a small internal study and reflects visual concordance rather than a large prospective clinical trial with prespecified performance measures. Broader testing across institutions, tumor types and sample qualities will be needed before the software’s clinical reliability can be fully established.

CnQuant could also extend copy-number interpretation beyond microarrays, according to its developers. The cohort atlas may serve as a reference when clinicians interpret targeted sequencing or newer nanopore sequencing results, both of which can produce ambiguous evidence for gains and losses depending on coverage, assay design and tumor purity. Because the platform is locally installable through Docker or Windows Subsystem for Linux, it does not require a cloud-based analysis service or extensive computing infrastructure. Its open-source code and public reference resources may make it easier for laboratories to inspect, adapt and integrate the system into their own workflows. The authors argue that existing tools, including Conumee 2.0 and SeSAMe, do not combine interactive graphical exploration, on-the-fly gene annotation, high processing speed and low resource requirements in the same way. If independent validation confirms the initial results, a tool that makes chromosome-scale abnormalities immediately visible could help transform copy-number data from an underused by-product of methylation testing into a practical component of personalized cancer diagnosis and treatment planning.

Colorectal cancer remains a formidable health burden globally, with a significant proportion of patients facing disease recurrence despite curative surgical resection. Traditional adjuvant chemotherapy protocols rely heavily on pathological staging and clinical risk factors, which, while informative, often lack the precision to tailor therapy according to residual tumor burden. This novel trial exploits tumor-informed ctDNA analysis, an innovative approach that tracks patient-specific somatic mutations, allowing unprecedented sensitivity in MRD detection at early postoperative stages.

The study design employs a multi-center platform trial framework registered under ClinicalTrials.gov identifier NCT05534087. It thoughtfully incorporates two parts: an initial prospective observational phase screening over 1,200 stage II and III colon cancer patients shortly after curative surgery, followed by a randomized controlled phase focusing on patients demonstrating postoperative MRD positivity. This strategic bifurcation ensures comprehensive evaluation of ctDNA’s prognostic and predictive potential and creates an evidence-based pathway to modify adjuvant chemotherapy intensity.

Central to the study is a hybrid-capture-based next-generation sequencing assay tailored to each patient’s unique tumor exome profile, enabling the tracking of up to 100 personalized somatic variants. By analyzing plasma samples collected 3 to 6 weeks after surgery, the research team can detect the presence of ctDNA fragments indicative of residual microscopic disease. This sensitive approach transcends traditional imaging and biomarker limitations, offering a real-time molecular snapshot of tumor dynamics poised to inform therapeutic decision-making.

Eligibility criteria meticulously define the patient cohort, encompassing adults aged 19 years and older, who have undergone curative resection for stage III or high-risk stage II colon adenocarcinoma and are candidates for standard adjuvant chemotherapy with FOLFOX or CAPOX regimens. Importantly, patients with no gross residual tumor focus are included, emphasizing the role of ctDNA as a molecular biomarker rather than a substitute for conventional pathological evaluation.

In the first phase, all enrolled patients receive a standard three-month course of adjuvant chemotherapy while awaiting MRD results, ensuring uniform initial treatment exposure. Subsequent molecular stratification determines further management: MRD-positive individuals qualify for enrollment in the interventional randomized trial, whereas MRD-negative patients are managed per physician discretion. This approach balances rigorous scientific inquiry with personalized clinical judgment.

The randomized controlled trial in Part 2 rigorously evaluates whether intensifying chemotherapy with a modified FOLFIRINOX regimen for an additional three months enhances outcomes compared to continuing standard FOLFOX/CAPOX therapy. Designed to enroll 236 MRD-positive patients, the trial is powered to detect a hazard ratio of 0.64 for three-year disease-free survival (DFS), with well-defined secondary endpoints including five-year overall survival, treatment-related toxicity, compliance, and patient-reported quality of life measures.

Critically, this study heralds a shift toward precision oncology in colon cancer, acknowledging the biological heterogeneity underpinning therapeutic responses. By focusing on measurable residual disease at the molecular level, researchers aim to circumvent the “one-size-fits-all” paradigm, offering intensified therapy only to those at demonstrable risk of recurrence. This paradigm has the potential not only to improve survival rates but to spare low-risk patients from the deleterious side effects of overtreatment.

The implications of ctDNA-directed therapy extend beyond colon cancer, suggesting a model applicable to various solid tumors where minimal residual disease is an elusive yet clinically decisive factor. Furthermore, the integration of tumor whole-exome sequencing with sophisticated ctDNA assays exemplifies the convergence of genomic medicine with routine clinical practice, reinforcing the feasibility of personalized cancer care.

Challenges remain, however, including the need for centralized, validated ctDNA testing infrastructure, harmonization of assay sensitivity and specificity, and addressing the psychological impact of MRD-informed treatment decisions on patients. Nevertheless, the ambitious scale and rigorous methodology of this trial establish a robust framework to overcome such barriers, setting the stage for regulatory approval and widespread clinical adoption.

Furthermore, the trial’s inclusion of patient-reported outcomes emphasizes a holistic approach to cancer care, recognizing that survival gains must be balanced against quality of life considerations. Data generated will elucidate not only the efficacy but also the tolerability and patient acceptability of intensified chemotherapy regimens, providing critical insights for oncologists and patients navigating complex treatment choices.

This pioneering research also underlines the importance of international collaboration, uniting multiple centers and leveraging diverse patient populations to enhance the generalizability of findings. Such cooperation accelerates the translation of molecular diagnostics into tangible clinical benefits and exemplifies the future direction of cancer research—multidisciplinary, precision-driven, and patient-centered.

As the field awaits results from this high-impact trial, clinicians and scientists alike are optimistic that ctDNA-guided adjuvant chemotherapy will evolve from a promising concept into a standard of care, fundamentally altering the therapeutic landscape of colon cancer. The anticipated survival improvements and reduction in recurrence represent a beacon of hope for patients worldwide battling this common malignancy.

In summary, the CLAUDIA colon cancer platform study embodies a transformative approach to managing postoperative colon cancer, leveraging cutting-edge ctDNA technology to personalize adjuvant chemotherapy. Its innovative design, comprehensive endpoints, and focus on clinical implementation mark a significant stride toward precision oncology that could redefine recovery trajectories and outcomes for countless patients facing this formidable disease.

Subject of Research: Circulating tumor DNA (ctDNA) guided adjuvant chemotherapy intensification in colon cancer.

Article Title: Platform study of circulating tumor DNA directed adjuvant chemotherapy in colon cancer (CLAUDIA colon cancer, KCSG CO22-12).

Article References:
Cha, Y., Cho, SH., Park, E.Y. et al. Platform study of circulating tumor DNA directed adjuvant chemotherapy in colon cancer (CLAUDIA colon cancer, KCSG CO22-12). BMC Cancer 25, 1373 (2025). https://doi.org/10.1186/s12885-025-14746-0

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14746-0